Eribulin usually refers to Eribulin Mesylate Injection, which is usually used for a course of six treatments, which is determined by the body’s physical condition and the severity of the disease. Elibrin mesylate injection is often used to treat patients with locally advanced or metastatic breast cancer who have received at least two prior chemotherapy regimens. It is usually used in a course of six treatments of 21 days each. The exact dosage, frequency, and duration of treatment may vary from patient to patient depending on a number of factors, including physical condition, severity of disease, and other factors. Neutropenia, anemia, thrombocytopenia, peripheral neuropathy and other adverse reactions may occur during drug administration. It is contraindicated in pregnant women. Drugs need to be used under the guidance of a doctor, do not blindly use the drug, the emergence of adverse reactions, it is recommended to seek medical attention in a timely manner in order to avoid delays in the condition.